ImaRx builds ultrasound contrast effort

Article

Ultrasound contrast developer ImaRx Pharmaceutical is rampingup its manufacturing capacity and personnel lineup as it preparesfor the commercial launches of several new products.The Tucson, AZ, company last month tapped Henry "Pete"Manspeaker

Ultrasound contrast developer ImaRx Pharmaceutical is rampingup its manufacturing capacity and personnel lineup as it preparesfor the commercial launches of several new products.

The Tucson, AZ, company last month tapped Henry "Pete"Manspeaker as vice president and director of clinical operationsof its newly formed clinical research department. Manspeaker wasmost recently director of clinical research at Alliance Pharmaceuticalof San Diego.

Manspeaker will work in conjunction with ImaRx Pharmaceutical'sU.S. licensee, Du Pont Merck Pharmaceutical, on the completionof clinical trials related to ImaRx's Aerosomes (MRX-115) microbubble-basedultrasound contrast agent technology (SCAN 12/13/95). Aerosomesis about to begin phase III clinical trials.

Other agents ImaRx is developing include gastrointestinal MRIagent LumenHance; gastrointestinal ultrasound agent SonoRx; TomoRx,a CT agent for the gastrointestinal tract; and MRX-408, a thrombus-specificultrasound contrast agent.

The company also announced that a physical plant expansion, whichwill result in the construction of a new 18,000-square-foot facility,should be finished by late 1997. Following the completion of theproject, the company anticipates that it will double its workforce to 50 employees.

In other personnel moves, ImaRx announced that Thomas Fritz hasbeen promoted from director of operations to vice president andchief operating officer.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.